This study included 22 subjects with confirmed clinical features consistent with PHMDS and molecular/cytogenetic diagnoses of PHMDS.r These subjects had previous chromosome microarray testing performed for 22q13 genomic deletion detection, as well as Sanger sequencing of SHANK3 gene in individuals without 22q13 deletion. This evidence concerns the gene SHANK3 and Phelan-McDermid syndrome.